SCOPUS 정보 검색 플랫폼

Multiple Sclerosis Journal

Volumn 18, Issue 11, 2012, Pages 1644-1646

Severe haematological complications during treatment with natalizumab

(3) Midaglia, L a Rodriguez Ruiz, M a Munoz Garcia D a

a UNIVERSITY HOSPITAL COMPLEX OF VIGO (Spain)

Author keywords

demyelination; disease modifying therapies

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; NATALIZUMAB;

ACUTE DISEASE; ANEMIA, HEMOLYTIC; CASE REPORT; CHEMICALLY INDUCED; FEMALE; HUMAN; IMMUNOLOGY; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PURPURA, THROMBOCYTOPENIC; SEVERITY OF ILLNESS INDEX; TIME;

ACUTE DISEASE; ANEMIA, HEMOLYTIC; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PURPURA, THROMBOCYTOPENIC; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 84868029862 PISSN: 13524585 EISSN: 14770970 Source Type: Journal
DOI: 10.1177/1352458512442262 Document Type: Article

Times cited : (15)

References (9)

1
- 33644584352
- A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis
- Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006 ; 354: 899-910
- (2006) N Engl J Med , vol.354 , pp. 899-910
- Polman, C.H.¹ O'Connor, P.W.² Havrdova, E.³

2
- 33644608613
- A randomized, placebo-controlled trial of natalizumab plus interferon beta-1a for relapsing multiple sclerosis
- Rudick RA, Stuart WH, Calabresi PA, et al. A randomized, placebo-controlled trial of natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006 ; 354: 911-923
- (2006) N Engl J Med , vol.354 , pp. 911-923
- Rudick, R.A.¹ Stuart, W.H.² Calabresi, P.A.³

3
- 54049087015
- Assessment: The use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review)
- Goodin DS, Cohen BA, O'Connor P, et al. Assessment: The use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review). Neurology. 2008 ; 71: 766-773
- (2008) Neurology , vol.71 , pp. 766-773
- Goodin, D.S.¹ Cohen, B.A.² O'Connor, P.³

4
- 34047272106
- Natalizumab treatment for multiple sclerosis: Recommendations for patient selection and monitoring
- DOI 10.1016/S1474-4422(07)70078-9, PII S1474442207700789
- Kappos L, Bates D, Hartung HP, et al. Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurol. 2007 ; 6: 431-441 (Pubitemid 46551850)
- (2007) Lancet Neurology , vol.6 , Issue.5 , pp. 431-441
- Kappos, L.¹ Bates, D.² Hartung, H.-P.³ Havrdova, E.⁴ Miller, D.⁵ Polman, C.H.⁶ Ravnborg, M.⁷ Hauser, S.L.⁸ Rudick, R.A.⁹ Weiner, H.L.¹⁰ O'Connor, P.W.¹¹ King, J.¹² Radue, E.W.¹³ Yousry, T.¹⁴ Major, E.O.¹⁵ Clifford, D.B.¹⁶

5
- 80051483071
- Immune thrombocytopenic purpura in a patient with multiple sclerosis treated with natalizumab
- Stosic M, De Jesus P, McCarthy J, et al. Immune thrombocytopenic purpura in a patient with multiple sclerosis treated with natalizumab. Neurology. 2011 ; 77: 505-507
- (2011) Neurology , vol.77 , pp. 505-507
- Stosic, M.¹ De Jesus, P.² McCarthy, J.³

6
- 77749266400
- Drug-induced immune hemolytic anemia
- Garratty G. Drug-induced immune hemolytic anemia. Hematology Am Soc Hematol Educ Program. 2009: 73-79
- Hematology Am Soc Hematol Educ Program , vol.2009 , pp. 73-79
- Garratty, G.¹

7
- 22544464411
- The changing spectrum of drug-induced immune hemolytic anemia
- DOI 10.1053/j.seminhematol.2005.04.004, PII S0037196305000570
- Arndt PA, Garratty G. The changing spectrum of drug-induced immune hemolytic anemia. Semin Hematol. 2005 ; 42: 137-144 (Pubitemid 41019442)
- (2005) Seminars in Hematology , vol.42 , Issue.3 , pp. 137-144
- Arndt, P.A.¹ Garratty, G.²

8
- 77949434753
- Drug-induced thrombocytopenia: Pathogenesis, evaluation, and management
- George JN, Aster RH. Drug-induced thrombocytopenia: pathogenesis, evaluation, and management. Hematology Am Soc Hematol Educ Program. 2009: 153-158
- Hematology Am Soc Hematol Educ Program , vol.2009 , pp. 153-158
- George, J.N.¹ Aster, R.H.²

9
- 54949143968
- Alemtuzumab vs. interferon beta-1a in early multiple sclerosis
- Coles AJ, Compston DA, et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med. 2008 ; 359: 1786-1801
- (2008) N Engl J Med , vol.359 , pp. 1786-1801
- Coles, A.J.¹ Compston, D.A.²

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.